4.4 Review

Pluripotent Stem Cells and Other Innovative Strategies for the Treatment of Ocular Surface Diseases

期刊

STEM CELL REVIEWS AND REPORTS
卷 12, 期 2, 页码 171-178

出版社

SPRINGER
DOI: 10.1007/s12015-016-9643-y

关键词

Pluripotent stem cells; Ocular surface diseases; Limbal stem cell deficiency; Cornea; Exosomes; Secreted microvesicles

资金

  1. French National Agency for Research [ANR 11 EMMA 023, ANR-13-PRTS-0001-02]

向作者/读者索取更多资源

The cornea provides two thirds of the refractive power of the eye and protection against insults such as infection and injury. The outermost tissue of the cornea is renewed by stem cells located in the limbus. Depletion or destruction of these stem cells may lead to blinding limbal stem cell deficiency (LSCD) that concerns millions of patients around the world. Innovative strategies based on adult stem cell therapies have been developed in the recent years but they are still facing numerous unresolved issues, and the long term results can be deceiving. Today there is a clear need to improve these therapies, and/or to develop new approaches for the treatment of LSCD. Here, we review the current cell-based therapies used for the treatment of ocular diseases, and discuss the potential of pluripotent stem cells (embryonic and induced pluripotent stem cells) in corneal repair. As the secretion of paracrine factors is known to have a crucial role in maintaining stem cell homeostasis and in wound repair, we also consider the therapeutic potential of a promising novel pathway, the exosomes. Exosomes are nano-sized vesicles that have the ability to transfer RNAs and proteins to recipient cells, and several studies demonstrated their role in cell protection and wound healing. Exosomes could circumvent the hurdles of stem-cell based approaches, and they could become a strong candidate as an alternative therapy for ocular surface diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell & Tissue Engineering

SOX2 Regulates P63 and Stem/Progenitor Cell State in the Corneal Epithelium

Swarnabh Bhattacharya, Laura Serror, Eshkar Nir, Dalbir Dhiraj, Anna Altshuler, Maroun Khreish, Beatrice Tiosano, Peleg Hasson, Lia Panman, Chen Luxenburg, Daniel Aberdam, Ruby Shalom-Feuerstein

STEM CELLS (2019)

Article Cell & Tissue Engineering

Extracellular Vesicles from Activated Dermal Fibroblasts Stimulate Hair Follicle Growth Through Dermal Papilla-Secreted Norrin

Alizee le Riche, Edith Aberdam, Laetitia Marchand, Elie Frank, Colin Jahoda, Isabelle Petit, Sylvie Bordes, Brigitte Closs, Daniel Aberdam

STEM CELLS (2019)

Article Cell Biology

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1MET/APR-246

Edith Aberdam, Lauriane N. Roux, Philippe-Henri Secretan, Franck Boralevi, Joel Schlatter, Fanny Morice-Picard, Stefano Sol, Christine Bodemer, Caterina Missero, Salvatore Cisternino, Daniel Aberdam, Smail Hadj-Rabia

CELL DEATH & DISEASE (2020)

Article Multidisciplinary Sciences

Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance

Valerie Barbier, Johanna Erbani, Corrine Fiveash, Julie M. Davies, Joshua Tay, Michael R. Tallack, Jessica Lowe, John L. Magnani, Diwakar R. Pattabiraman, Andrew C. Perkins, Jessica Lisle, John E. J. Rasko, Jean-Pierre Levesque, Ingrid G. Winkler

NATURE COMMUNICATIONS (2020)

Article Cell Biology

Acute Myeloid Leukemia Chemo-Resistance Is Mediated by E-selectin Receptor CD162 in Bone Marrow Niches

Johanna Erbani, Joshua Tay, Valerie Barbier, Jean-Pierre Levesque, Ingrid G. Winkler

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Article Cell Biology

TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin

Anna Maria Lena, Erica Foffi, Massimiliano Agostini, Mara Mancini, Margherita Annicchiarico-Petruzzelli, Daniel Aberdam, Tania Velletri, Yufang Shi, Gerry Melino, Ying Wang, Eleonora Candi

Summary: The transcription factor p53 plays a crucial role in controlling the differentiation process of mesenchymal stem cells. Other members of the p53 family, such as p63 and p73, may also be involved in this process. Specifically, TAp63 isoforms are shown to be upregulated during osteogenic differentiation, potentially impacting bone-related diseases and breast cancer metastasis.

CELL CYCLE (2021)

Article Ophthalmology

The antipsychotropic drug Duloxetine rescues PAX6 haploinsufficiency of mutant limbal stem cells through inhibition of the MEK/ERK signaling pathway

Orly Dorot, Lauriane N. Roux, Lea Zennaro, Keren Oved, Dominique Bremond-Gignac, Edward Pichinuk, Daniel Aberdam

Summary: The study found that Duloxetine can enhance PAX6 activity and restore normal function of limbal cells in patients with aniridia-related keratopathy, and activates PAX6 expression by inhibiting the ERK pathway. This discovery is of great importance for the development of topical treatment drugs for aniridia.

OCULAR SURFACE (2022)

Article Ophthalmology

Pathophysiology of aniridia-associated keratopathy: Developmental aspects and unanswered questions

L. Latta, F. C. Figueiredo, R. Ashery-Padan, J. M. Collinson, J. Daniels, S. Ferrari, N. Szentmary, S. Sola, R. Shalom-Feuerstein, M. Lako, S. Xapelli, D. Aberdam, N. Lagali

Summary: Aniridia, a rare congenital disease, is characterized by progressive corneal defects and ocular surface pathology, presenting challenges in clinical management due to its bilateral nature and the presence of multiple coexisting ocular and systemic morbidities. The role of limbal stem cells and the ocular microenvironment in the pathogenesis of aniridia-associated keratopathy (AAK) has been questioned in light of new evidence, highlighting the need for further research to deepen the understanding and develop new treatments for this blinding ocular surface disease.

OCULAR SURFACE (2021)

Article Ophthalmology

National protocol for diagnosis and care of congenital aniridia: Summary for the attending physician

D. Bremond-Gignac, M. Robert, A. Daruich, V Borderie, F. Chiannbaretta, S. Valleix

Summary: Congenital aniridia is a rare ocular disease primarily caused by abnormalities in the PAX6 gene. It can lead to visual impairment, photophobia, and has significant impacts on personal and professional life. Treatment involves medical and surgical management, as well as comprehensive rehabilitation care.

JOURNAL FRANCAIS D OPHTALMOLOGIE (2022)

Review Ophthalmology

Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches

Alejandra Daruich, Melinda Duncan, Matthieu P. Robert, Neil Lagali, Elena V. Semina, Daniel Aberdam, Stefano Ferrari, Vito Romano, Cyril Burin des Roziers, Rabia Benkortebi, Nathalie De Vergnes, Michel Polak, Frederic Chiambaretta, Ken K. Nischal, Francine Behar-Cohen, Sophie Valleix, Dominique Bremond-Gignac

Summary: Congenital PAX6-aniridia is not only characterized by the absence of the iris, but it is also associated with other ocular abnormalities and systemic features, making it a complex syndromic disorder. Foveal hypoplasia is now recognized as a more frequent feature than iris hypoplasia and plays a major role in visual prognosis. Genetic diagnosis of aniridia is challenging due to the genetic complexity caused by PAX6-related developmental genes. Targeted Next-Generation Sequencing combined with Whole-Genome Sequencing can increase the genetic diagnostic yield of aniridia.

PROGRESS IN RETINAL AND EYE RESEARCH (2023)

Article Multidisciplinary Sciences

Fibroblast growth factor-2 bound to specific dermal fibroblast-derived extracellular vesicles is protected from degradation

Isabelle Petit, Ayelet Levy, Soline Estrach, Chloe C. Feral, Andrea Goncalves Trentin, Florent Dingli, Damarys Loew, Jieqiong Qu, Huiqing Zhou, Clotilde Thery, Celine Prunier, Daniel Aberdam, Olivier Ferrigno

Summary: This study found that fibroblast growth factor-2 (FGF2) binds to extracellular vesicles (EVs) derived from dermal fibroblasts, protecting FGF2 from degradation and promoting wound healing. This provides a new approach for using EVs as a potential tool for delivering FGF2.

SCIENTIFIC REPORTS (2022)

Review Ophthalmology

Future directions in managing aniridia-associated keratopathy

Arianne J. H. Van Velthoven, Tor P. Utheim, Maria Notara, Dominique Bremond-Gignac, Francisco C. Figueiredo, Heli Skottman, Daniel Aberdam, Julie T. Daniels, Giulio Ferrari, Christina Grupcheva, Carina Koppen, Mohit Parekh, Thomas Ritter, Vito Romano, Stefano Ferrari, Claus Cursiefen, Neil Lagali, Vanessa L. S. Lapointe, Mor M. Dickman

Summary: Congenital aniridia is a panocular disorder characterized by iris hypoplasia and aniridia-associated keratopathy (AAK), leading to loss of vision. The understanding of the molecular pathogenesis of AAK may provide new insights for its management, as there is currently no approved therapy to delay or prevent its progression. This review discusses the biological mechanisms involved in AAK development and explores potential future treatment options including surgical, pharmacological, cell therapies, and gene therapies.

SURVEY OF OPHTHALMOLOGY (2023)

Review Cell Biology

MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges

Petros Moustardas, Daniel Aberdam, Neil Lagali

Summary: This review article focuses on the roles of MAPK signaling pathways in ocular pathophysiology and the potential to treat eye diseases. It summarizes the current research on MAPK-targeting compounds in the context of macular degeneration, cataract, glaucoma, keratopathy, and other ocular diseases. Challenges in overcoming eye toxicity of some MAPK inhibitors are also discussed.
Article Cell & Tissue Engineering

Production and Limbal Lineage Commitment of Aniridia Patient-Derived Induced Pluripotent Stem Cells

Tanja Ilmarinen, Meri Vattulainen, Jeyalakshmi Kandhavelu, Dominique Bremond-Gignac, Daniel Aberdam, Heli Skottman

Summary: Congenital aniridia is caused by mutations on the PAX6 gene leading to reduced PAX6 protein and abnormal eye development. Aniridia-associated keratopathy (AAK) is characterized by progressive corneal opacification similar to late-onset limbal stem cell (LSC) deficiency. This study generated induced pluripotent stem cells (hiPSC) from AAK patients and found that PAX6 haploinsufficiency affects LSC lineage commitment.

STEM CELLS (2023)

Article Biochemistry & Molecular Biology

Identification of the regulatory circuit governing corneal epithelial fate determination and disease

Jos G. A. Smits, Dulce Lima Cunha, Maryam Amini, Marina Bertolin, Camille Laberthonniere, Jieqiong Qu, Nicholas Owen, Lorenz Latta, Berthold Seitz, Lauriane N. Roux, Tanja Stachon, Stefano Ferrari, Mariya Moosajee, Daniel Aberdam, Nora Szentmary, Simon J. van Heeringen, Huiqing Zhou

Summary: This study uses multiomics and gene regulatory network analysis to compare the limbal stem cells that maintain the cornea with keratinocytes which maintain the skin, revealing an intriguing interplay of transcription factors that drive epithelial similarities and differences in health and disease.

PLOS BIOLOGY (2023)

暂无数据